5:43 PM
 | 
Apr 29, 2014
 |  BC Extra  |  Company News

EC approves Teva's DuoResp Spiromax

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said the European Commission approved DuoResp Spiromax budesonide/formoterol to treat asthma and chronic obstructive pulmonary disease (COPD). The company plans to launch the...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >